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Received May 14, 2015; accepted July 15, 2015AbstractBackground: Image-guided percutaneous radiofrequency ablation (RFA) has been the most commonly used modality in the treatment of
nonresectable hepatic malignancies. However, tumors in the subcapsular location are still technically challenging. This study was undertaken to
evaluate the feasibility, safety, and efficacy of computed tomographic-guided percutaneous RFAwith hydrodissection for hepatic malignancies in
the subcapsular location.
Methods: A total of 103 patients with 253 hepatic lesions were treated with computed tomographic-guided percutaneous RFA. Computed
tomographic-guided percutaneous RFA with hydrodissection was performed in 15 patients with 15 hepatic nodules. All tumors located in the
hepatic subcapsular location were considered difficult to treat on planning sonography. Hydrodissection was performed with 5% dextrose in
water or saline solution in displacing adjacent structures  10 mm away from the liver capsule. Two RFA systems with multitined expandable
electrodes or straight internally cooled single electrodes were used for treatment of hepatic malignancies. The feasibility, safety, and efficacy of
this technique were analyzed on follow-up contrast-enhanced computed tomography or magnetic resonance imaging.
Results: Hydrodissection was successfully achieved in 15 (100%) patients, displacing the adjacent structures  10 mm that were originally <
10 mm away from the liver capsule with administration of a mean of 376 mL of dextrose in water or saline solution. The average distance
between an adjacent structure and the liver capsule after hydrodissection was 1.50 ± 0.40 cm and 0.11 ± 0.15 cm prior to hydrodissection, which
was statistically significant ( p < 0.001). No complication related to hydrodissection occurred during the follow-up period. The primary technical
success rate of percutaneous RFA for tumor was 100% (15/15) at 1-month follow-up imaging. There were three minor complications (20%, 3/15)
related to the RFA procedure.
Conclusion: Computed tomographic-guided percutaneous RFA with hydrodissection is a feasible, safe, and effective technique in the treatment
of hepatic malignancies in the subcapsular location.
Copyright © 2015, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
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Among the methods used to treat hepatic malignancies,
surgical resection is the proven curative treatment when he-
patocellular carcinoma (HCC) or metastatic disease is limited
to the liver. However, a majority of patients cannot undergo
curative resection because of medical comorbidities and/or
severely compromised liver function.1,2
Since the 1990s, radiofrequency ablation (RFA) has been
most widely used for the treatment of hepatic malignancies,
achieving good results in local tumor control and low
morbidity and mortality.2e5 Nonetheless, when the tumor is
located in the subcapsular location, it is difficult to place the
radiofrequency electrode into the tumor by sonographic
guidance because of the partial visibility of the tumor or a poor
electrode path. This situation also increases the risk of thermal
injury to the adjacent structure resulting in major
complications.6e8
Several technical methods have been developed to prevent
complications and to increase the accuracy of electrode
placement, including different approaches, e.g., percutaneous,
laparoscopic, or open laparotomy,9 artificial ascites or pleural
effusion,10,11 and different guiding techniques.2,10,12,13 To our
knowledge, limited data are available on the usefulness of
computed tomographic-guided percutaneous RFA with
hydrodissection in treating hepatic malignancies in the sub-
capsular location. Thus, we undertook this study to evaluate
the feasibility, safety, and efficacy of computed tomographic-
guided percutaneous RFA with hydrodissection for hepatic
malignancies in the subcapsular location.
2. Methods2.1. Patient demographics and medical record reviewThe Institutional Review Board for Human Investigation of
the Tri-Service General Hospital, National Defense Medical
Center, Taipei, Taiwan granted approval to conduct this study
(TSGHIRB 098-05-260). Written informed consent was ob-
tained from each patient prior to the percutaneous RFA of
hepatic malignancies. Between January 2009 and August 2012
(3.5 years), a total of 103 patients with 253 hepatic tumors
were treated with computed tomographic-guided percutaneous
RFA at our institution. All patients met the following criteria
for percutaneous RFA: up to five nodules with diameters of up
to 8 cm, absence of refractory ascites and extrahepatic disease,
a platelet count  50,000/mm3, and prothrombin activity 
50%. Among the study participants, 15 patients with 15 he-
patic nodules underwent computed tomographic-guided
percutaneous RFA with hydrodissection because all tumors
were located in the subcapsular region (a portion of the tumor
located within 5 mm of the liver capsule) and near vital
structure (the distance between liver capsule and vital structure
< 10 mm). All tumors were considered difficult to treat
because of the poor tumor visibility or lack of safe radio-
frequency electrode inserted pathway on planning sonography.
The 15 patients (age range, 50e80 years; mean age, 63.7years) had the following origin of hepatic malignancies: five
HCCs, five colorectal carcinomas, two breast carcinomas, and
one ovarian carcinoma. The tumor diameters prior to ablation
ranged from 1.5 cm to 6.0 cm (mean, 3.30 ± 1.25 cm). The
follow-up period for all treated lesions ranged from 3 months
to 36 months.2.2. Hydrodissection techniqueAll patients were interviewed prior to the treatment, and all
procedures for hydrodissection and percutaneous RFA were
performed by one of the two interventional radiologists with 8
years and 12 years of experience in percutaneous RFA of
hepatic tumors. Hydrodissection with 5% dextrose in water
(D/W) or saline solution was performed with a 21-gauge
needle (Chiba needle; Cook Incorporated, Bloomington, IN,
USA) connected to a 50-mL syringe via connecting tubing.
The choice of the puncture site for hydrodissection was based
on the position of the patient and the discretion of the operator.
After administering a local anesthetic to the skin at the
puncture site, a 21-gauge needle was advanced into the peri-
hepatic space with the goal of placing the needle tip near the
interface between the hepatic tumor and the adjacent structure
under computed tomographic or sonographic guidance. A 50-
mL bolus of D/W or saline solution at room temperature was
then hand-injected into the perihepatic space. Repeat
computed tomography (CT) imaging after the initial bolus of
D/W or saline solution was performed to confirm the location
of the needle tip and to evaluate the distribution of the solu-
tion. An additional 50 mL of D/W or saline solution was
injected every 2 minutes until a separation of  10 mm be-
tween the liver capsule and the adjacent structure was ach-
ieved. At this point, we considered the hydrodissection
technically successful.2.3. Radiofrequency ablation systemTwo RFA systems were used. A 200-W generator with
multitined expandable electrodes was used in 10 patients with
10 lesions (Boston Scientific, Waltham, MA, USA). A 200-W
generator with straight internally cooled single electrode,
which was composed of a 3-cm exposed electrode with a ther-
mocouple on the tip and a pulsed current, was used in five pa-
tients with five lesions (Covidien Inc., Burlington, MA, USA).
The choice of system used was at the discretion of the operator.2.4. Ablation procedureIn all cases, the treatment rationale was to achieve local
control. Percutaneous RFA was performed under computed
tomographic guidance. All RFA procedures were performed
with either intravenous conscious sedation (n ¼ 10) or general
anesthesia (n ¼ 5). Overlapping ablations, ranging from one to
six ablations per tumor (mean 2.8), were performed using both
generator systems. The RFA algorithm for the internally cooled
electrodes consisted of a pulsed current, with each ablation
lasting 12 minutes. With the 3-cm expandable electrode
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and the average time for each ablation was 7e12 minutes.
During the RFA, the distance between the liver capsule and
adjacent structure was monitored by CT in each ablation. If the
distance was < 10 mm, an additional 50 mL of D/W or saline
solution was injected until the separation was  10 mm.2.5. Treatment course and follow-upAll patients underwent immediate follow-up without
contrast-enhanced CT to evaluate immediate complications
after percutaneous RFA. Follow-up contrast-enhanced CT or
magnetic resonance imaging (MRI) of the abdomen was per-
formed 1 month after the ablation to evaluate treatment effi-
cacy. Triple-phase CT or MRI studies of the abdomen were
obtained. The initial unenhanced scan of the abdomen was
followed by enhanced scans obtained at 30 seconds, 70 sec-
onds, and 180 seconds after intravenous contrast administra-
tion. Patient MRIs consisted of pre- and postgadolinium
enhanced multiplanar T1- and T2-weighted images of the
abdomen. A nonenhancing zone of ablation with a diameter
greater than that of the hepatic tumor nodule in the axial,
coronal, and sagittal planes was considered as a criterion for
complete treatment. When nodular or irregular peripheral
enhancement was identified within or along the margins of the
ablation zone, additional radiofrequency treatments of a pre-
sumed residual viable tumor were performed, and follow-up
imaging was obtained 1 month later. Thereafter, follow-up
imaging was performed every 3 months for 1 year followed
by semiannual follow-up imaging.2.6. Definition of technical success of hydrodissectionTechnical success was defined as the ability to separate the
liver capsule and adjacent structure by a distance of  10 mm
during RFA. To estimate the technical feasibility of hydro-
dissection, we recorded the number of needle punctures
required to select the peritoneal space, the total amount of
solution injected, the maximum distance between the liver
capsule and adjacent structure, and the kind of image guidance
used for hydrodissection.
To estimate the safety of hydrodissection, we evaluated
whether the injected solution was shifted to the pleural space
or retroperitoneal space. We then measured the Hounsfield
units (H) of the injected solution between the RFA zone and
the adjacent structure on CT, which was performed prior to and
immediately after RFA to evaluate whether the injected solu-
tion may have a role in the development of hemoperitoneum
after RFA. Follow-up contrast-enhanced CT or MRI study of
the abdomen was performed 1 month after the ablation to
evaluate delayed complications related to hydrodissection.2.7. Definition of therapeutic effectiveness of
percutaneous RFAThe results of each CT and MRI study were evaluated
retrospectively by a consensus reading by two abdominalradiologists with 7 years and 10 years of experience in
abdominal imaging. The diameter of the tumors prior to the
ablation was measured directly from the vascular phase im-
ages where the tumors were best visualized in an axial, cor-
onal, or sagittal plane in CT or MRI studies. The data analyzed
included tumor diameter, RFA electrode type (multitined
expandable or internally cooled), and a diameter of the zone of
ablation. The evolution of the diameter of the zone of ablation
was based on the 1-month follow-up image study and was
reported as the largest diameter of the nonenhancing zone in
an axial, coronal, or sagittal plane where the zone of ablation
was the largest. Nodular or irregular contrast enhancement
within or at the margins of the zone of ablation during portal
venous phase imaging after 1 month follow-up examination
was considered to be the criterion of local tumor progression.
Complications related to percutaneous RFA were also recor-
ded. To assess the therapeutic efficacy of percutaneous RFA,
we evaluated the primary technical effectiveness in terms of
residual tumor with 1 month follow-up CT or MRI.2.8. Statistical analysisContinuous data were expressed as mean ± standard devi-
ation. The differences in qualitative variables were analyzed
using Chi-square test, and differences between the means of
the two groups were analyzed using Student t test. All p values
were calculated using two-tailed tests. A p value < 0.05
indicated a statistically significant difference. The analyses
were performed using the SPSS version 11.0 (SPSS Inc.,
Chicago, IL, USA).
3. Results3.1. Technical feasibility, efficacy, and safety of
hydrodissectionFifteen structures were identified to be < 10 mm away from
the liver capsule prior to hydrodissection. These included the
ascending colon (n ¼ 7), diaphragm (n ¼ 7), and peritoneum
(n ¼ 1). Hydrodissection with D/W or saline solution was
technically successful in all patients. The average distance
between adjacent structure and liver capsule after hydro-
dissection was 1.50 ± 0.40 cm (range, 1.0e2.1 cm) and
0.11 ± 0.15 cm (range, 0e0.5 cm) prior to hydrodissection,
which was statistically significant ( p < 0.001). The technical
details of hydrodissection for each patient are shown in Table
1. The average number of needle punctures for hydro-
dissection was 1.2 ± 0.41 (range, 1e2). The average amount
of solution for hydrodissection was 376.00 ± 340.50 mL
(range, 100e1500 mL). Hydrodissection was performed on
seven patients with lesions located over the medial margin of
the liver surface under computed tomographic guidance
(Fig. 1), and eight patients with lesions located over the lateral
margin of the liver surface under sonographic guidance
(Fig. 2).
No injected solution was observed in the right pleural space
or retroperitoneal space in any patients during the immediate
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the ablative zone after RFAwas 22.29 ± 5.19 H (range, 14e32
H) and 9.20 ± 3.95 H (range, 4e15 H) prior to RFA, which
was statistically significant ( p < 0.001). No patients had
abnormal vital signs until the day after the procedure. The
injected solution was completely absorbed in all patients at the
1-month follow-up CT or MRI. No delayed complications
related to hydrodissection such as hemoperitoneum or peri-
tonitis developed during the 1-month follow-up.3.2. Therapeutic effectiveness of percutaneous RFAThe primary technical effectiveness was 100% (15/15) for
percutaneous RFA with hydrodissection and 90% (215/238)
for percutaneous RFA at 1 month follow-up CT or MRI. The
local tumor progression was identified in four lesions (26.7%,
4/15) of percutaneous RFA with hydrodissection and 71 le-
sions (29.8%, 71/238) of percutaneous RFA during the follow-
up period. The patients' demographics and tumor characteris-
tics are shown in Table 2. Three minor complications related
to percutaneous RFA (20%, 3/15) included asymptomatic
pneumothorax (n ¼ 2; Fig. 1), and a small perihepatic biloma
(n ¼ 1; Fig. 2). All minor complications were managed
conservatively.
4. Discussion
Many previous investigations have described imaging-
guided percutaneous RFA for hepatic malignancies in the
subcapsular location as a technique with an elevated safety
profile and minimally invasive in nature.11,14e17 However,
collateral thermal injury to the adjacent structures, such as the
gastrointestinal tract, gallbladder, and diaphragm, is still a
technical complication of percutaneous RFA because of poor
localization of the tumor.6,18 Recently, sonography-guided
percutaneous RFA with hydrodissection has been recognized
as a useful modality for the treatment of HCC in the hepatic
dome.10,11,19 Previous clinical studies using computed
tomographic-guided percutaneous RFA with hydrodissection
are relatively limited.20 The results of our study showed that
hydrodissection is technically feasible and effective in
improving protection of the adjacent structures by separating
them away from the liver capsule. The purpose of the present
study was to evaluate the feasibility, safety, and efficacy of
computed tomographic-guided percutaneous RFA with
hydrodissection for hepatic malignancies in the subcapsular
location.
Regarding the methods for hydrodissection, the use of a
Chiba needle or angiosheath for insertion into the peritoneal
space under sonographic guidance appears to be the most
popular technique.3,4,14,17,21 However, the tip of the needle or
sheath is difficult to identify on sonography when the tumor is
located in the medial margin of the right lobe of liver (seg-
ments V and VI). In this study, we used a 21-gauge Chiba
needle for hydrodissection under sonographic guidance, when
the tumors were located in the lateral margin of right lobe liver
or hepatic dome (n ¼ 8) and under computed tomographic
Fig. 1. A 50-year-man with colorectal hepatic metastasis in the subcapsular location over the segment V after computed tomographic-guided percutaneous
radiofrequency ablation (RFA) with hydrodissection. (A) Axial contrast-enhanced computed tomography shows a metastatic nodule about 4.3 cm in size in the
subcapsular location over the segment V (arrow). (B) Hydrodissection was performed to displace the ascending colon under computed tomographic guidance. (C)
Percutaneous RFA of the metastatic lesion with a multitined expandable electrode was performed. Asymptomatic pneumothorax occurred during the RFA pro-
cedure. (D) Local tumor progression is identified at the 10-month follow-up contrast-enhanced computed tomography (arrow).
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of right lobe liver (n ¼ 7). To confirm that the distance be-
tween the liver capsule and adjacent structures was  10 mm,
all the procedures of hydrodissection were monitored by CT
during the ablation. Overall, the technical success rate of
hydrodissection was 100% (15/15).
Song et al16 reported that potential complications related to
hydrodissection are bleeding, peritonitis, and tumor seeding.
Our study showed that hydrodissection is a safe technique
without complications. The H units of the injected solution
between the ablative zone and adjacent structure after RFA
were mildly higher than those of the injected solution prior to
RFA (22.29 ± 5.19 vs. 9.20 ± 3.95 H). No active bleeding or
injected solution shifted to the pleural space or retroperitoneal
space was identified in the immediate follow-up CT study after
RFA. All patients showed complete absorption of the injected
solution on the 1-month follow-up imaging study.Rhim et al10 reported that a mean of 348 mL of D/W was
infused into the perihepatic space on sonography to improve
the visibility in 93.4% (15/16) HCC nodules located in the
hepatic dome. Song et al16 also reported that a mean of
436 mL of D/W solution was injected into the perihepatic
space on sonography to create a distance of  10 mm from the
adjacent organ. In our study, hydrodissection induced with
376.00 ± 340.50 mL of D/W or saline solution created a
distance of  10 mm between the liver capsule and adjacent
structure on CT. When classified by tumor location, the group
of tumors located in the medial margin of right lobe liver had a
larger amount of infused solution than the group of tumors
located in the lateral margin (528.57 ± 433.84 mL vs.
242.50 ± 164.03 mL). One patient with a colorectal hepatic
metastatic nodule in the medial margin of segment V of liver
had 1500 mL saline solution for hydrodissection during the
RFA procedure because of posture change, resulting in infused
Fig. 2. A 51-year-woman with breast carcinoma with hepatic metastasis in the subcapsular location over the segment V after computed tomographic-guided
percutaneous radiofrequency ablation (RFA) with hydrodissection. (A) Axial contrast-enhanced computed tomography shows a metastatic nodule about 3.3 cm
in size in the subcapsular location over the segment V (arrow). (B) Hydrodissection was performed to displace the peritoneum under sonographic guidance. (C)
Percutaneous RFA of the metastatic lesion with a multitined expandable electrode was performed. One tine of the expandable electrode penetrated the liver
capsule. (D) No local tumor progression but a small perihepatic biloma formation (arrow) is noted and other recurrent metastatic lesions over the right lobe liver are
also identified at the 13-month follow-up contrast-enhanced computed tomography.
98 C.-H. Liu et al. / Journal of the Chinese Medical Association 79 (2016) 93e100solution shifting away after the hydrodissection. The results of
our study showed that a larger amount of infused solution for
hydrodissection was needed for tumors located in the medial
margin of the right lobe of liver.
D/W, saline solution, and sterile water have been used for
hydrodissection during percutaneous RFA to protect structure
adjacent to the ablation zone. Laeseke et al22 reported that D/
W is particularly well suited to serve as a protective fluid.
There are several advantages of D/W acting as insulator during
RFA: it is nearly isoosmolar, is well tolerated in virtually every
body space, and is rapidly absorbed. Most importantly, it is
nonionic and thus does not conduct electricity or produce
heating because of ionic agitation. In our study, D/W was used
for hydrodissection in 12 patients and saline solution in three
patients. No thermal injury of adjacent perihepatic structure or
large shifts in systemic fluid was identified at the immediate
follow-up CT.Some authors have reported that tumors with a subcapsular
location and abutting hollow viscera have a high rate of local
tumor progression and increased risk of complications.23,24
However, our results showed that the complete necrosis after
RFA on the 1-month follow-up imaging was obtained in 15
(100%) of the 15 lesions. Additionally, local tumor progres-
sion was 26.7% (4/15) during the follow-up period. In the
present study, all patients underwent percutaneous RFA under
computed tomographic guidance to place the electrode into the
lesion. When classified by the RFA system, the group of tu-
mors treated using a multitined expandable electrode had a
higher local tumor progression rate than the group of tumors
treated using a straight internally cooled single electrode
(40%, 4/10 vs. 0%, 0/5), but without statistical significance
( p ¼ 0.099, Chi-square test). The use of the straight internally
cooled single electrode facilitated to place the electrode tip
closer to the liver capsule than the use of the multitined
Table 2
Patients' demographic and tumor characteristics for 15 hepatic malignancies.
Characteristic Value
Age (y) 63.67 ± 9.80 (50e80)
Sex (male/female) 9/6
Tumor origina 7/5/2/1
Tumor size (cm) 3.30 ± 1.25 (1.5e6.0)
RFA systemsb 10/5
No. of ablations per tumor 2.80 ± 1.52 (1e6)
Zone of ablation size (cm) 4.59 ± 1.02 (3.2e6.5)
Primary technical effectiveness after RFA 100 (15/15)
Local tumor progression rate after RFA 26.7 (4/15)
Average local tumor progression time (mo) 5.75 ± 3.10 (3e10)
Average follow-up time (mo) 11.73 ± 8.65 (3e36)
Data are presented as mean ± standard deviation (range) or % (n/N ), unless
otherwise indicated.
RFA ¼ radiofrequency ablation.
a Hepatocellular carcinoma/colorectal carcinoma/breast carcinoma/ovarian
carcinoma.
b Boston Scientific, Waltham, MA, USA/Covidien Inc., Burlington, MA,
USA.
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during percutaneous RFA.
It is easy to monitor the ablative zone on computed
tomographic guidance using a multitined expandable elec-
trode, but the shape of the ablation zone is not circular, and has
the potential to puncture the adjacent structure.25 In the pre-
sent study, a small perihepatic biloma was observed in one
patient after RFA. The patient with a metastatic nodule in the
lateral margin of segment V was treated using a multitined
expandable electrode. During the RFA procedure, one tine of
the electrode penetrated the liver capsule resulting in thermal
injury of the capsule after RFA. To prevent such complication,
the use of computed tomographic guidance for monitoring the
location of the deployed radiofrequency electrode is
recommended.
This study has several limitations. First, the number of
patients and tumors were small, limiting the power of the
study. Second, we could not evaluate the true benefit of the
hydrodissection to prevent thermal injury of the adjacent
structures during RFA because we could not conduct a ran-
domized controlled study. Third, the overall survival was not
included in the outcome measures because the purpose of our
study was to evaluate the benefit of computed tomographic-
guided percutaneous RFA with hydrodissection for hepatic
malignancies in the subcapsular location.
In conclusion, the present results indicated that computed
tomographic-guided RFA with hydrodissection is a feasible,
safe, and effective treatment for hepatic malignancies in the
subcapsular location. This procedure is an alternative tech-
nique when percutaneous RFA under sonographic guidance is
difficult to perform because of poor tumor visibility or lack of
safe radiofrequency electrode inserted pathway.
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